Curis Lifesciences IPO
Live Updates, GMP, Subscription Data, and Financial Details
IPO Overview
Listed
Dates
Nov 07 to Nov 11 2025
Price Band
₹120 - 128
Current GMP
₹146.1 (+14.14%)
Subscription
74.39 times
IPO Details
| IPO Date | November 7, 2025 to November 11, 2025 |
| Listing Date | November 14, 2025 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹120 to ₹128 per share |
| Issue Price Final | ₹128 per share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 21,50,000 shares (aggregating up to ₹27.52 Cr) |
| Reserved for Market Maker | 1,08,000 shares (aggregating up to ₹1.38 Cr)RS Wealth Management Private Limited |
| Net Offered to Public | 20,42,000 shares (aggregating up to ₹26.14 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 59,34,434 shares |
| Share Holding Post Issue | 80,84,434 shares |
IPO Date
November 7, 2025 to November 11, 2025
Listing Date
November 14, 2025
Face Value
₹10 per share
Issue Price Band
₹120 to ₹128 per share
Issue Price Final
₹128 per share
Lot Size
1,000 Shares
Sale Type
Fresh Capital
Total Issue Size
21,50,000 shares (aggregating up to ₹27.52 Cr)
Reserved for Market Maker
1,08,000 shares (aggregating up to ₹1.38 Cr)RS Wealth Management Private Limited
Net Offered to Public
20,42,000 shares (aggregating up to ₹26.14 Cr)
Issue Type
Bookbuilding IPO
Listing At
NSE SME
Share Holding Pre Issue
59,34,434 shares
Share Holding Post Issue
80,84,434 shares
IPO Subscription Details
| Anchor Investors | 1 |
| Market Maker | 1 |
| QIB (Ex Anchor) | 96.17 |
| Non-Institutional Buyers*** | 115.46 |
| bNII (bids above ₹10L) | 142.74 |
| sNII (bids below ₹10L) | 60.38 |
| Individual Investors (IND category bidding for 2 Lots) | 44.28 |
| Total ** | 74.39 |
Anchor Investors
1
Market Maker
1
QIB (Ex Anchor)
96.17
Non-Institutional Buyers***
115.46
bNII (bids above ₹10L)
142.74
sNII (bids below ₹10L)
60.38
Individual Investors (IND category bidding for 2 Lots)
44.28
Total **
74.39
Day Wise Sub
| Day | QIB (Ex Anchor) | NII* | NII (> ₹10L) | NII (< ₹10L) | Individual Investors | Total |
|---|---|---|---|---|---|---|
| Day 1 Nov 7, 2025 | 8.34 | 1.19 | 1.53 | 0.50 | 0.87 | 3.07 |
| Day 2 Nov 10, 2025 | 8.34 | 4.06 | 4.60 | 2.95 | 3.80 | 5.15 |
| Day 3 Nov 11, 2025 | 96.17 | 115.46 | 142.74 | 60.38 | 44.28 | 74.39 |
DayDay 1
Nov 7, 2025
QIB (Ex Anchor)8.34
NII*1.19
NII (> ₹10L)1.53
NII (< ₹10L)0.50
Individual Investors0.87
Total3.07
DayDay 2
Nov 10, 2025
QIB (Ex Anchor)8.34
NII*4.06
NII (> ₹10L)4.60
NII (< ₹10L)2.95
Individual Investors3.80
Total5.15
DayDay 3
Nov 11, 2025
QIB (Ex Anchor)96.17
NII*115.46
NII (> ₹10L)142.74
NII (< ₹10L)60.38
Individual Investors44.28
Total74.39
Day Wise GMP
| Date | Price | GMP | Estimate List Price |
|---|---|---|---|
| 14-11-2025 | 128.00 | 9(7.03%) | 137 |
| 13-11-2025 | 128.00 | 9(7.03%) | 137 |
| 12-11-2025 | 128.00 | 9(7.03%) | 137 |
| 11-11-2025 | 128.00 | 6(4.69%) | 134 |
| 10-11-2025 | 128.00 | 8(6.25%) | 136 |
| 09-11-2025 | 128.00 | 8(6.25%) | 136 |
| 08-11-2025 | 128.00 | 8(6.25%) | 136 |
| 07-11-2025 | 128.00 | 7.5(5.86%) | 135.5 |
| 06-11-2025 | 128.00 | 7.5(5.86%) | 135.5 |
| 05-11-2025 | 128.00 | 6(4.69%) | 134 |
| 04-11-2025 | 128.00 | 0(0.00%) | 128 |
| 03-11-2025 | 128.00 | 0(0.00%) | 128 |
| 01-11-2025 | 128.00 | 0(0.00%) | (0.00%) |
| 31-10-2025 | 128.00 | 0(%) | (%) |
Date14-11-2025
Price128.00
GMP9(7.03%)
Estimate List Price137
Date13-11-2025
Price128.00
GMP9(7.03%)
Estimate List Price137
Date12-11-2025
Price128.00
GMP9(7.03%)
Estimate List Price137
Date11-11-2025
Price128.00
GMP6(4.69%)
Estimate List Price134
Date10-11-2025
Price128.00
GMP8(6.25%)
Estimate List Price136
Date09-11-2025
Price128.00
GMP8(6.25%)
Estimate List Price136
Date08-11-2025
Price128.00
GMP8(6.25%)
Estimate List Price136
Date07-11-2025
Price128.00
GMP7.5(5.86%)
Estimate List Price135.5
Date06-11-2025
Price128.00
GMP7.5(5.86%)
Estimate List Price135.5
Date05-11-2025
Price128.00
GMP6(4.69%)
Estimate List Price134
Date04-11-2025
Price128.00
GMP0(0.00%)
Estimate List Price128
Date03-11-2025
Price128.00
GMP0(0.00%)
Estimate List Price128
Date01-11-2025
Price128.00
GMP0(0.00%)
Estimate List Price(0.00%)
Date31-10-2025
Price128.00
GMP0(%)
Estimate List Price(%)
IPO Important Dates
| IPO Open Date | Fri, Nov 7, 2025 |
| IPO Close Date | Tue, Nov 11, 2025 |
| Tentative Allotment | Wed, Nov 12, 2025 |
| Initiation of Refunds | Thu, Nov 13, 2025 |
| Credit of Shares to Demat | Thu, Nov 13, 2025 |
| Tentative Listing Date | Fri, Nov 14, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Tue, Nov 11, 2025 |
IPO Open Date
Fri, Nov 7, 2025
IPO Close Date
Tue, Nov 11, 2025
Tentative Allotment
Wed, Nov 12, 2025
Initiation of Refunds
Thu, Nov 13, 2025
Credit of Shares to Demat
Thu, Nov 13, 2025
Tentative Listing Date
Fri, Nov 14, 2025
Cut-off time for UPI mandate confirmation
5 PM on Tue, Nov 11, 2025
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,56,000 |
| Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,56,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,84,000 |
| S-HNI (Max) | 7 | 7,000 | ₹8,96,000 |
| B-HNI (Min) | 8 | 8,000 | ₹10,24,000 |
ApplicationIndividual investors (Retail) (Min)
Lots2
Shares2,000
Amount₹2,56,000
ApplicationIndividual investors (Retail) (Max)
Lots2
Shares2,000
Amount₹2,56,000
ApplicationS-HNI (Min)
Lots3
Shares3,000
Amount₹3,84,000
ApplicationS-HNI (Max)
Lots7
Shares7,000
Amount₹8,96,000
ApplicationB-HNI (Min)
Lots8
Shares8,000
Amount₹10,24,000
Financial Information
| Period Ended | 31 Jul 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Period Ended | 31 Jul 2025 | 31 Mar 2025 | 31 Mar 2024 |
| Assets | 56.29 | 42.53 | 33.88 |
| Total Income | 19.51 | 49.65 | 35.87 |
| Profit After Tax | 2.87 | 6.11 | 4.87 |
| EBITDA | 4.24 | 9.54 | 8.39 |
| NET Worth | 19.10 | 16.23 | 5.87 |
| Reserves and Surplus | 13.16 | 10.29 | 5.37 |
| Total Borrowing | 15.32 | 15.62 | 17.09 |
Period EndedPeriod Ended
31 Jul 202531 Jul 2025
31 Mar 202531 Mar 2025
31 Mar 202431 Mar 2024
Period EndedAssets
31 Jul 202556.29
31 Mar 202542.53
31 Mar 202433.88
Period EndedTotal Income
31 Jul 202519.51
31 Mar 202549.65
31 Mar 202435.87
Period EndedProfit After Tax
31 Jul 20252.87
31 Mar 20256.11
31 Mar 20244.87
Period EndedEBITDA
31 Jul 20254.24
31 Mar 20259.54
31 Mar 20248.39
Period EndedNET Worth
31 Jul 202519.10
31 Mar 202516.23
31 Mar 20245.87
Period EndedReserves and Surplus
31 Jul 202513.16
31 Mar 202510.29
31 Mar 20245.37
Period EndedTotal Borrowing
31 Jul 202515.32
31 Mar 202515.62
31 Mar 202417.09
Peers Comparison
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio |
|---|---|---|---|---|---|---|
| Curis Lifesciences Limited | 10.29 | 10.29 | 27.34 | 37.62 | ||
| Sotac Pharmaceuticals Limited | 4.32 | 4.32 | 47.99 | 18.30 | 9.00 | 2.72 |
| Lincoln Pharmaceuticals Limited | 41.11 | 41.11 | 335.34 | 12.21 | 12.27 | 1.58 |
Company NameCuris Lifesciences Limited
EPS (Basic)10.29
EPS (Diluted)10.29
NAV (per share) (Rs)27.34
P/E (x)
RoNW (%)37.62
P/BV Ratio
Company NameSotac Pharmaceuticals Limited
EPS (Basic)4.32
EPS (Diluted)4.32
NAV (per share) (Rs)47.99
P/E (x)18.30
RoNW (%)9.00
P/BV Ratio2.72
Company NameLincoln Pharmaceuticals Limited
EPS (Basic)41.11
EPS (Diluted)41.11
NAV (per share) (Rs)335.34
P/E (x)12.21
RoNW (%)12.27
P/BV Ratio1.58
IPO Reservation
| Market Maker Shares Offered | 1,08,000 (5.02%) |
| QIB Shares Offered | 10,18,000 (47.35%) |
| − Anchor Investor Shares Offered | 6,09,000 (28.33%) |
| − QIB (Ex. Anchor) Shares Offered | 4,09,000 (19.02%) |
| NII (HNI) Shares Offered | 3,08,000 (14.33%) |
| − bNII > ₹10L | 2,06,000 (9.58%) |
| − sNII < ₹10L | 1,02,000 (4.74%) |
| Retail Shares Offered | 7,16,000 (33.30%) |
| Total Shares Offered | 21,50,000 (100.00%) |
Market Maker Shares Offered
1,08,000 (5.02%)
QIB Shares Offered
10,18,000 (47.35%)
− Anchor Investor Shares Offered
6,09,000 (28.33%)
− QIB (Ex. Anchor) Shares Offered
4,09,000 (19.02%)
NII (HNI) Shares Offered
3,08,000 (14.33%)
− bNII > ₹10L
2,06,000 (9.58%)
− sNII < ₹10L
1,02,000 (4.74%)
Retail Shares Offered
7,16,000 (33.30%)
Total Shares Offered
21,50,000 (100.00%)
Information about company
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.
The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.
The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.
Products:
General pharmaceutical tablets and capsules
Oral liquids
External preparations
Sterile ophthalmic ointments
The company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.
As of July 31, 2025, the company has 95 permanent employees.
Competitive Strengths:
Experienced Promoters and Management Team
Wide range of Products
Strategic Location of Manufacturing Facility
Scalable Business Model
Quality assurance
Objectives of IPO
The Company Curis Lifesciences IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
S.No.
Objects of the Issue
Expected Amount (₹ in crores)
1
Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities
2.44
2
Capital Expenditure towards Construction of a Storage Facility
3.62
3
Pre-payment/Repayment of outstanding Secured Loans
1.86
4
Product Registrations in other countries
2.69
5
Funding our Working Capital Requirements
11.25
6
General Corporate Purposes
2.85
Disclaimer
All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application.
No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever
Please read all Tearms and conditions , and agree to use the App